Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KP-1199 Safety, PK, and PD Study in Healthy Adults
NCT03880487Phase 1Terminated
- Sponsor
- Kalyra Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- Apr 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KP-1199 in pain (3 arms), sponsored by Kalyra Pharmaceuticals. Primary endpoint: Number of Participants with Treatment Emergent Adverse Events. Started Mar 2019; status: terminated.
02
Drugs
KP-1199
03
Conditions
pain
Beyond the preview
Go deeper on NCT03880487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03880487.